Credit: Coherus. The on-body injector includes features such as a retractable needle mechanism, an indicator, status light and auditory signal to help patients confirm the dose has been administered.

Udenyca Onbody is expected to be available in the first quarter of 2024 and will be supplied in a carton containing 1 on-body injector co-packaged with 1 prefilled syringe. The Food and Drug ...

REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, NASDAQ: CHRS) today announced the launch of UDENYCA ONBODY™, the company's on-body injector (OBI) ...

The Food and Drug Administration approved Udenyca Onbody, an administration device for Udenyca, a biosimilar of Neulasta. The Food and Drug Administration (FDA) approved Udenyca Onbody, an injector ...

(RTTNews) - Coherus BioSciences, Inc. (CHRS) said the FDA issued a Complete Response Letter regarding the Biologics License Application supplement for UDENYCA ONBODY, the company's on-body injector ...

After months of delays following an FDA review of its Udenyca OnBody biologics license application, Coherus has finally received FDA approval for the product. Coherus is planning commercial ...

“Those independent patients, with families and busy lifestyles, or those who just have a hard time coming back to the office the day after chemotherapy—that’s who is really going to benefit from the ...

If you’re receiving cancer treatment that increases your risk of infections, your doctor might suggest Udenyca as a treatment option. It’s a prescription drug used to prevent neutropenia (a low level ...

- UDENYCA ® is the only pegfilgrastim therapy delivered in a convenient, easy-to-administer prefilled autoinjector to offer in-clinic and at-home administration options for cancer patients undergoing ...

– Unique, automatic, retractable needle mechanism engineered to maximize safety and comfort for cancer patients receiving pegfilgrastim – REDWOOD CITY, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- ...

Coherus BioSciences, Inc. (NASDAQ:CHRS) shares are trading higher Wednesday after the company announced the FDA approval of its pegfilgrastim delivery device, Udenyca Onbody. Coherus BioSciences ...